Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

PWE-153 cost effectiveness of Rifaximin-a in the reduction of recurrence of overt hepatic encephalopathy

Poole, Christopher David, Conway, P., Nanuwa, K., Joseph, B., Bannister, Christian ORCID: and Currie, Craig John 2014. PWE-153 cost effectiveness of Rifaximin-a in the reduction of recurrence of overt hepatic encephalopathy. Gut 63 (Suppl) , A191. 10.1136/gutjnl-2014-307263.413

Full text not available from this repository.


Introduction: Hepatic encephalopathy (HE) is associated with high morbidity and mortality. Rifaximin-α is effective in reducing the recurrence of episodes of overt HE. The aim was to characterise the cost effectiveness of rifaximin-α versus standard care (lactulose). Methods: This economic evaluation used a Markov state transition model. The outcome was the incremental cost effectiveness ratio (ICER), derived from estimates of the cost/quality adjusted life years. The payer perspective was that of UK National Health Service. Outcome data were from two trials of rifaximin-α. Population outcome data were from a complementary study of patients with liver cirrhosis treated within the NHS. Cost data (GBP£2012) were derived from published sources. Health-related utility was estimated indirectly from disease-specific trial QoL data. The time horizon was five years. Costs and benefits were discounted at 3.5%. Extensive sensitivity analysis was carried out. Results: The average cost of the included elements of care was £15,476 in the rifaximin-α arm and £4,486 in the lactulose arm, a difference of £10,990. The corresponding values for benefit was 2.36 QALYs, and 1.83 QALYs per person, respectively; a difference of 0.53 units. This translated into a base-case ICER of £20,852/QALY. Key parameters that impacted the ICER included the event-free survival pattern, ranging from an ICER of £13,919 using an exponential model, to £21,425/QALY using a log-logistic model. Evaluation to 10 years resulted in an ICER of £19,122/QALY. Conclusion: Rifaximin-α in patients with liver cirrhosis was cost effective compared to standard care, reducing episodes of overt hepatic encephalopathy.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Computer Science & Informatics
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects: R Medicine > R Medicine (General)
Publisher: BMJ Publishing Group Ltd
ISSN: 0017-5749
Last Modified: 27 Oct 2022 08:26

Citation Data

Actions (repository staff only)

Edit Item Edit Item